Navidea Biopharmaceuticals Third Quarter 2012 Earnings and Business Update Conference Call Invitatio
Navidea Biopharmaceuticals Third Quarter 2012 Earnings and Business Update Conference Call Invitation
- Conference Call Scheduled for 5:00 PM ET, Thursday, November 8th-
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the third quarter of 2012 on Thursday, November 8, 2012 after market close. The announcement of results will be followed by a conference call with the investment community on the same day at 5:00 PM ET.
Navidea's President and CEO, Dr. Mark Pykett, Executive Vice President and Chief Business Officer, Dr. Thomas Tulip, and Senior Vice President and CFO, Brent Larson, will provide a development and business update and will discuss the Company's financial results for the third quarter of 2012 during the conference call. The conference call can be accessed as follows:
CONFERENCE CALL INFORMATION | ||||||||
TO PARTICIPATE LIVE: | TO LISTEN TO A REPLAY: | |||||||
Date: | November 8, 2012 | Available until: | November 22, 2012 | |||||
Time: | 5:00 PM ET | Toll-free (U.S.) Dial in # : | (877) 660-6853 | |||||
International Dial in # : | (201) 612-7415 | |||||||
Toll-free (U.S.) Dial in # : | (877) 407-8031 | |||||||
International Dial in # : | (201) 689-8031 | Replay passcode: | ||||||
Account # | 286 | |||||||
Conference ID #: | 403335 | |||||||
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms - Lymphoseek®, NAV4694, NAV5001 (CFT) and RIGScanTM - to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Navidea Biopharmaceuticals, Inc.
Brent Larson, Sr. VP & CFO, 614-822-2330
KEYWORDS: United States North America Ohio
INDUSTRY KEYWORDS:
The article Navidea Biopharmaceuticals Third Quarter 2012 Earnings and Business Update Conference Call Invitation originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
